CTI Startup
CTI Startup is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at CTI Startup.
CTI Startup is a company.
Key people at CTI Startup.
Key people at CTI Startup.
CTI Clinical Trial & Consulting (CTI) is a global clinical research organization (CRO) founded as a Cincinnati startup in 1999, specializing in advancing medical therapies through clinical trials and consulting services.[3][8] It serves pharmaceutical sponsors, biotech firms, and developers of innovative treatments—particularly in cell and gene therapy (CGT)—by providing end-to-end trial management, from design to execution, solving the challenges of complex, regulated clinical development to accelerate patient access to life-changing therapies like those for cancer and diabetes.[3][8][9] With operations across five continents, CTI combines large-scale global reach with personalized service, contributing to over half of FDA and EMA CGT approvals while embracing AI-driven optimizations and remote monitoring for efficiency.[3]
CTI was founded in 1999 in Cincinnati, Ohio, by Tim Schroeder, its current Chairman, CEO, and key leader, initially focusing on transplantation research as a startup.[3] The idea emerged from a commitment to advancing medical science and patient outcomes, evolving over 25+ years into a leading mid-sized CRO with expertise in CGT—entering that space nearly 15 years ago—and expanding services to meet client needs in innovative trial designs.[3] Early traction came from Ohio's life sciences ecosystem, scaling through talent retention, service diversification, and pivotal contributions to groundbreaking therapies, including some of the world's first approved CGT products, cementing its role as an Ohio success story with global impact.[3]
CTI rides the explosive growth of cell and gene therapy (CGT), a trend where Ohio leads nationally, fueled by demand for cures in oncology, diabetes, and rare diseases amid regulatory accelerations by FDA/EMA.[3] Timing is ideal as biotech funding rebounds and AI transforms trials—reducing timelines by enabling real-time data and decentralized models—positioning CTI to capitalize on market forces like rising therapy approvals (over half via their work) and global trial complexity.[3] It influences the ecosystem by mentoring Ohio's life sciences hub, fostering collaborations that advance therapies faster, and setting standards for mid-sized CROs blending scale with agility in a $50B+ industry shifting toward tech-enabled, patient-centric research.[3]
CTI is poised for accelerated expansion by doubling down on AI, CGT, and emerging modalities like precision medicine, potentially capturing more market share as trials decentralize and approvals surge.[3] Trends like wearable tech and regulatory harmonization will shape its path, evolving its influence from regional powerhouse to indispensable global partner in faster, cheaper therapy development. As a startup-turned-leader, CTI exemplifies how focused innovation in clinical research propels the next wave of medical breakthroughs, tying back to its Cincinnati roots in advancing human health.
